-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HMqGloRvROz3sWu+wptS2LIfMRAqaRL+tmoag7UqiuP5m0TqE/0JgmSEHCv/2lBo
 b8b5tKUoOd4WVXasXHou7g==

<SEC-DOCUMENT>0001193125-10-020903.txt : 20100203
<SEC-HEADER>0001193125-10-020903.hdr.sgml : 20100203
<ACCEPTANCE-DATETIME>20100203170633
ACCESSION NUMBER:		0001193125-10-020903
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100128
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100203
DATE AS OF CHANGE:		20100203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		10571430

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported) January&nbsp;28, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registration as
specified in charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02453</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last
report.) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01. <U>Entry into a Material Definitive Agreement</U>. </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;26, 1999, Repligen Corporation (the &#147;Company&#148;) entered into a Supply Agreement with Amersham Biosciences AB, a GE Healthcare company
(the &#147;Original Agreement&#148;). The Original Agreement governed the manufacturing of Amersham Biosciences AB&#146;s recombinant Protein A (&#147;Protein A&#148;). On February&nbsp;3, 2005, the Company entered into Amendment No.&nbsp;1 to the
Original Agreement which extended the term of the Original Agreement through the end of 2010 and expanded the manufacturing to include an additional Amersham Biosciences AB recombinant Protein A. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company entered into the Strategic Supplier Alliance Agreement with GE Healthcare Bio-Sciences AB, a GE Healthcare company (&#147;GEHC&#148;), on
January&nbsp;28, 2010 (the &#147;Supply Agreement&#148;) and the Original Agreements were simultaneously terminated. GEHC sells chromatography products, which incorporate Protein A, to the biopharmaceutical industry for the manufacture of monoclonal
antibodies. Pursuant to the terms of the Supply Agreement, the Company has agreed to manufacture and sell to GEHC and GEHC has agreed to purchase two forms of GEHC proprietary recombinant Protein A (the &#147;Products&#148;) from the Company. The
average price charged by the Company for the Products is subject to volume-based decreases, as set forth in the Supply Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
connection with the Products sold by the Company pursuant to the Supply Agreement, the Company provides a warranty to GEHC that the Products will conform strictly to and be manufactured in accordance with the specifications set forth in the Supply
Agreement and shall be free from defects for a period of time as specified in the Supply Agreement. In the event that GEHC exercises any rights in connection with this warranty, the Company will replace the returned Product within 30 days of receipt
of the non-conforming or defective Product by the Company or promptly thereafter provide GEHC a refund. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of the Supply Agreement
commenced on January&nbsp;1, 2010 and continues for a period of five years. The Company and GEHC will start negotiations 18 months prior to the expiration of the term to decide whether to renew the Supply Agreement. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the Supply Agreement is qualified in its entirety by reference to the full Supply Agreement, which will be filed as an exhibit
to the Company&#146;s Annual Report on Form 10-K for the year ending March&nbsp;31, 2010. The Company intends to submit a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), requesting that it be permitted to redact certain portions of the Supply Agreement. The omitted material will be included in the request for confidential treatment. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.02. <U>Termination of a Material Definitive Agreement</U>. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Please see the disclosure set forth under Item&nbsp;1.01 regarding the expiration of the Original Agreement, which is incorporated by reference into this Item&nbsp;1.02. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01. <U>Regulation FD Disclosure</U>. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">On January&nbsp;28, 2010, the Company issued a press release announcing it entered into the Supply Agreement with GEHC. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this
Current Report on Form 8-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information provided in this Item&nbsp;7.01 and the exhibit attached hereto shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such a filing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. <U>Financial Statements and Exhibits</U>.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman"
SIZE="2">99.1 Press Release by Repligen Corporation, January&nbsp;28, 2010. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: February&nbsp;3, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;W<SMALL>ALTER</SMALL> C.
H<SMALL>ERLIHY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Walter C. Herlihy</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President and Chief Executive Officer</B></FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated January 28, 2010.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="6"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g54242g48e17.jpg" ALT="LOGO"></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 Seyon Street</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite 100</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02453</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">781-250-0111</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">781-250-0115</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Whitehouse </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">VP, Market Development </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781) 419-1812 </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Announces Long Term Supply Agreement with GE Healthcare for </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recombinant Protein A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; January&nbsp;28,
2010</B> &#150; Repligen Corporation (NASDAQ: RGEN) Repligen Corporation (NASDAQ: RGEN) announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for
recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world&#146;s leading supplier of recombinant Protein A and has manufactured recombinant Protein A
for GE Healthcare for more than 10 years. This agreement provides for Repligen to continue to be a strategic supplier to GE Healthcare through 2014. GE Healthcare sells chromatography products which incorporate Repligen&#146;s recombinant Protein A
to the biopharmaceutical industry for the manufacture of monoclonal antibodies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased to continue our long standing
relationship with GE Healthcare,&#148; stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. &#147;This agreement ensures continuity in the supply of high quality recombinant Protein A supported by our business
continuity plans and quality systems that are required by the biopharmaceutical industry.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are currently more than 25 monoclonal
antibodies that have received regulatory approval with more than 200 products in various stages of clinical development. The worldwide revenues from this class of drug exceeded $35 billion in 2009. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Repligen Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen
Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world&#146;s leading supplier of recombinant Protein A, the sales of which partially fund the advancement
of our development pipeline while supporting our financial stability. Repligen&#146;s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from
<U>www.repligen.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management&#146;s strategy, plans and objectives
for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product
development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative
relationships, the market </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-more- </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A,
January&nbsp;28, 2010 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Page 2 of 2 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of
incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability
to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products,
the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our
volatile stock price, and other risks detailed in Repligen&#146;s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the
announcements described herein. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g54242g48e17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g54242g48e17.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)0"3`P$1``(1`0,1`?_$`'4```("`@,!`0``````
M```````)"`H&!P$$!0(+`0$`````````````````````$```!@(!`P(#!@0'
M```````"`P0%!@<!"`D`$@H1$Q05%B$Q(C(C%V%6&!E!,R0U)S<:$0$`````
M````````````````_]H`#`,!``(1`Q$`/P"YMR`[6)-'=*]EMLU3,ADAU&53
M(YHR1IS7FM;=)I8426W0R-+G(@E0H0I)#+7!$C,-++&8`)^<@"(7IC(4D8GY
MDF]4\;SW6#\94+F;6E5B0*G*)O\`<,B;TZ\!)2@:(]8T158G)5A(/`/)8A8'
M@`PY]/3.,Y#*8EYI]T0>QV9@VBXY4D3B9XTIL@2Q.PI7'+':V=4,8,O3/'K#
MAY3:_#+P`62DIRAM*4"!D/Q17YL!>TH^YJ^V*IRK[YJAZ^H:TN&"1>QH,\Y(
M,2'+XS+FA*]-1BM$=Z'H%X$JL(%"<S&#$YX1ECQ@0<XZ#:?0'0'0'0)OYP^4
MY=Q(:?,>Q,<K^-6G-Y?<<1J>)P:4OKBP-BXQZ9)5)WMT.6-*=2OR%I8XD?G&
M`A[?>-+[L^F?3(:S@_*Y>+]P:N'*K)*!CK?<+Q5\IG5?41%#)E,69V7K+.7U
MM4Z59E(E2RM>BDN1H')=\*$&2D:@8@&!"#)F`S+@WY"=L>2G6JR;ZVHH&)Z\
MK6*XW"M8'&(XS3YC5/S.Q1*+OKS)'%%8#BO<!IANLFPC3F$8`2(:0X.?40<^
M@1PW9Y]\PS8IZT5XRM7ICR-;F1L:Q)/VV#KQ-E*4TO0G%IEZ6>3Q(0J(7.+&
MK'[#F7@]L:VY2+"90ZE+`FI0!"NUN4[R7=.XPY[`[6\4&N$OUVC244@GZ&BY
M^I=)O"(LC*"I=7)Q71BY[B<&M"UH^\U6X'1U:B1EEC,.&44$0L!8CXY>0:B^
M3;5J&[34(:ZHV!]6.,9E\,D@$Q<KK>PV`"04D@\D"B.4(C5B$M>G5)E)(\E+
M6Y6F4AP#W?;`$ZN@.@.@.@.@JH>87?N*KXGR:I1KA$.VRNP%:0$Y(4/(#5$5
MA.':VWQ1GMS@0DQ#U!VDDS'W9^*#C/W^F07'X\G,SQ)<=/&=7M'7QLX.%7E)
M+&M*T[5BZ6G;NDA;.^2.1_3T=3C?8Q73PQ.)PJ[B+(8,2=2:``AY+SGN`+&`
M@5SK;FPWR%MI=0-6.*^H9Y?C[51,_$]VR;7CM$RW`5CN,-1]BI4_HD3U$:G@
M9$:RL<7=^*;D85*_/M@Q@OO/!Z_)3R;E>.[Q]Z7:`4`F8+AW/,HB(P>)GO*)
M8OB\29HNW)HU([E>HRE,2N+R=+YZ%:3&6?(RRU!Y*@:@0BT8DRH$U[.U9Y95
M"ZNR#D@N;=65Q5AB;.U6).J3C5H(6N=UY%G=:WAROD=*LE?MU.%IH_\`,2A.
M382K6*T*<)GOD>I1X0`^OC'YN[&VBX.=K-W;P&R)=@].(A>$7F<A9FE$T-$\
MF4)JUOG%92\B/$EA:&MQE9TH;D*M(G`%&-S(.&2222:6G+"O/Q;<@GDN<F\(
MV&JO6.Z$LN<`J(*7)=IKE2UO#8U1+44FE)A\,@)K'6^0+)_9IJX@U2I"W/:Q
MM0-)8B2T.3\JA!X.K_+!S,\6_+1`--.1.[9K=<7DEL5K7%O06Q),CLUH'$KA
M7LB*.6K4L[-3!>D&&A)(B7-,00<0F4!)-0K$A9^,X3A++S:[M6O]@Z$ZDQ\1
MBM<G9K'NIZ9DPAF'KW"8O+'6U=^B<(NT1P3(U("ROL[LY/SC'W]`Q/G@VJNO
MAFX?=!:#U1LEPIRZ2EE.4DEE4<2L2MS+A--4NJQ8QZ=._-;RA&-VE86?"@S!
M7?\`ZH7H+'=]H<[&<E.TFEWC&TGLG;-O2>:;N;;0"/1>$6A(`-#9*&M\V-6R
MV?M,E0)6-J:$:%=7%!@-&UF%IL9*<DB0PW(LB%D0-CX(>.2%\=>@-21S+"EQ
M?MUQ:-W+LI-U1`#9/(+%F344_%Q5Q=3096G,M9H';#.B([O9]XE2KP#!ZQ0,
M895(N<WAPP)]BDDWYUP.#@3I'G]H6R%4K3&XQD]M=6U6##2<F5)S,8,*'C&1
MEF!SG[<XST&IN(RJ.*K1S3G8:U=!]AUU@:DAGLTM.W+-E<\*F,8A3[`("QJ)
MF6B<$T4B^4+<P0M(B/4%^RI.$'M_4&+&`X!<=4WES-\['U9=^GVP#!Q8<=*:
M5O\`$Z4G"FLFVS-CMA4\8<5S.Y3<],ZGI"F!APXIS"1X;G-I(2*RQHP#=#$J
MA3@/<X[ML^2[37EU_M`<CM],VX$<N>D7BZM:-@B8P@CDK]J/-TB>CT3Q\`WH
ME0FYP;X'(DRU&YFN2I&XMZ8:9:-,HS@88AM1R;\HDWYZ[!XYN/!;!Y-%H#KP
MQ-CZQV,R,&*BJZPY)%V:82+86U).WQAPL=Q9Z]9K!;D:5A0N*<EQ?0(4^2C/
M=-*/")/)W.>=?A*245NY..45NW2@<YN]BK>R*'>Z.BE=0]0Y/++(Y:"-LD>0
M?.2OIEU9XJO28<6HQC=4)_PXP`'@8\EA=O\`KT[^5WK_`*[^O?RA_P`[^5_R
M?[U_#[OX=!^?7YK]V+IILKH[J9'CAKU<.K.8VNO948L&&JY!<DR0P6+)S20Y
M[LK"DU7*?9#G[>U;G./S=!8NJOQ>N'-JJ>N&*R=0$$HL1MKN'M,^E@KAOQN5
MR&:(XVW))3(<IFBTD#8A4.SX6>I[$I!)!0C/0L``8P'`4W.*FKD5*^4@CH;3
M>13-DIFMMJ=FJ_`3B1N*P3C2=8,-G`D$:E2_!H,RAA[(Y\.2)=@T1IP$QX\Y
M4!"9@/?YOHT1M7Y-SM0UW7(KUR@*N::R4S&[C5^U@JK8NZ51")(Q2EO-<G=@
M1(DIT_EJE5A0-<D(3'K!G"-!@&18!BF]O#WK5I_!&ENWD\DG9U@AMMY4,""#
M25FL6V#9PW93#5KAK*WB=RS9V<HH666$*A:I;\M@#3"BAFX,-*`(.GNE1VO_
M`!9>,38$%UAV`E.P$*Y']EJV?X?;$NK)VIM\DL1?4,8DYI;=!)$,4@21I3#]
M?C!D*E`"LK4SO@T`?9-*$,&O^)Y:VK-;<-[>M':E60Z41^W;KEVR`Y',(W&E
M<4?!OV$L>>9B-W<$0VUJ.JEF8QIU9^0IA%`$$(^XLS`0KOB>$/.UY1D8GU&I
M5DEUQJBT*RE2F9DI%)3:?0^IQ<?5N4O6#4$@.1--K3QJRD:?>++.SB0(PF``
M/OP$-A;^=G(=Y=%/TB7@;W#:>NC7RL52;':>29$M?HZGO2W&TP.`C`60%]#(
MTYG=C[,^OK]O09UYB<_>M@N1+1#2&&*1KG9@KM`I2MQ61F%@L'9JT4T,;$9I
M(,_J+/E=>-A@<>G=@M7CT_-T#"?+PI1?6/'=Q\AB#"L=:5UGO>&P22MR0L7P
MJ)E252HC4&,<"P8$6D1&HXHI;P'#]``/6EE>O<:'&0N'4S:M:[`T[7=P5/(&
MB7U9:<(8Y;#7QE5$JVQSC<@;"E*0(#$PQ!*.3E&Y(4$9[34QY8RC`A,`(.`J
M6^0%5O"5QL:46<WLFEFGC=M]>4+D$%UTB#+5L.S/&EYDR8UD<KF-(3)_F#`Q
M5JC6'."9R."$I0]$)4A>1#,%V!#N\(7+M,_#(KF.1A,M:'W8A%6$ML9R3EC)
M5XB^Q5W%61@:L80@&2G=H+AG9#>_\Z<_V\_8/TZ!@>E'!WL^KT_UB=JBYT=Z
MJWK:2435\OB$#K$;2CKZ*M4RA[3*L,T1(2RLHKY(E4/!F"1=N!F!_$/\6<]!
M]\9&DFM<NY89GL*BY5]F>1K9KC^B4FIN?FVO7[NIA,#S/FN<1`B)([H5951=
MY5M"M^D0PMK4M4]BLM6(?;[8_4.KXU9`-D]N^:GDC6DX7)[PV\6U'63T,'?E
M/!(<ZR27F-B-08')F4QD8D<1`/`1=N?@0>N/4./0./(MQ_4WR"\'G'6FQ\>U
MV/M";>]H-&/U<9A$+>8PT`5FI<?F!]&D3/\`$+'IC!8O\.[H+=_0(!W`\>C6
MG=?D,B/(=;UWWM]9PR1TH\M52M`Z^#6`FJDU3*XMD4/`XPU?)A,4G<VL\]RQ
MA=@X0W!1[(RL9!V`_P"Z"O-I-XZFO&C&^#EOY6^Q-_RNR7YTMIPD41G*:KE\
M0=R+@^;GR!%DYO@C=(F_*-R<P*$ZA,L+49RGP68,91AH!AFW+/X^6G'+-*6&
MVI\^SJDM@(ZP)HH&VZQPRJLRJ,-YJDYH9K`B;^B4-TD"Q&+#<(E9!S>X%E#]
MD:@P@LDHL(!:A^'CQ\T%8C+8]]63:NWAL;6)US/7TW0,$&JE4I2&@/2"ED7C
MPG-\E:1.:7C.41[N6VJ0^I:E,>4(1>06+YK]OA,DG'YIQ#$I"<AI8K"MY7%6
M<@M.0'#TNC]6U<C0-:4):=.2D+CT@3IBP`"$(3.P&,8QZ=!-NQO#/T^M<FIY
M3';VM?7M\35/5C!;T*BD?B\PB\AGL9A+"QS"61HQ[.0.$4<)@\-QR]<68-R2
MY7GF&DE%`'[6`L*<:G$_I]Q55@[5]K%$7,3_`#`;<ILRW9TN2/\`:=DK&H!X
M6T,A?$C>U-Z%D:<JSLHFMN2(FY,(XPS!0CS3CC`B-JGP":Y:L\CUB\FR*ZKQ
ML^\;%D=V2U4Q3XR!BAS)(;S<7)3)7!G`Q1%J?`9;&UZ5H$0#%8P@2'Y"/OSC
M&>@XNO@#UQO[E#BG*;8UTW<Z6A"I_4$_CU3A_;_%4(5-*,\<;X<S8(.AQTH&
MT_,XV6Y*,9</=,6'&YP,(!8"$&_;#Z]T]M92UAZ]WY"6RPZDM%@.CLQBCKD\
MLE:C$<2K2*T2U(:G7M+TS.24E8@7)32E2%:04>2,!I818"L;$/%QG5`.;VR:
M8<R6^FK5*/3LN<<U+%W):J*2%KSA&FEEO$1L.M6$U?C`^SXT;%E2,.,9,$,7
MJ+(2<2>,1H2JU_O2L)_-K_N&]=B6>-,UB;I6]-6RQMCD2..3.-S;X2!.TM8G
M>,PU&[+8R4D6#+0'."MO-&G4*S@=O:#C[0TJU[NG3Y9HO9\-#*M>5]31FFS8
MR>I&D7)XQ"VIH;8BO;'1$$@YKD<84,")<@6$8`),N2EFAQ^'TZ"O]#O&5GU<
M1=31E<\S7(K!-0E!ZT@&O,7E1+/A)'G%0(]PCJ&4-\@31Q`B7A&+!X"(T4E/
M&,8S"!9&+&0>-JMQV:TZ/ZL/.IVJ,965##7UDDJ9VF:!22\V2]S"3L0V-;9D
MFDSNF49D4V(+P4,@:@KX-,%.4G(3E)2BR`ACW&/QQ5#Q::P)-6Z7D\TFL9!.
MY?8CI++!$Q#E3Y(I@-O+5'.`HXT,;5[:%K9T:,GL3A%[*8/=D0O7/08Q-N+^
MI;"Y.ZEY2)785C.=JTC3KE3=<UB9F+YJYC:W9OGC>ND("1,(Y,.0FEV.Z#[\
M+PEX&8#\/H#&.@9CT!T!T!T!T!T%:#DZ_P#/G_<4I;^X]\1_7!\BI;]I?G/]
M3_T_],_N*_\`[7=W[??\2?)_K[YC\5\=^#N]WXW]+H++_0'0'0'0'0'0'0'0
*'0'0'0'0'0?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
